Brind.
  1. Revelation Biosciences, Inc. is advancing its Gemini program and plans to engage with the FDA later this year.

Gemini, a product candidate from Revelation Biosciences, is undergoing a Phase 1b clinical trial for Chronic Kidney Disease (CKD).

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Gemini, a product candidate from Revelation Biosciences, is undergoing a Phase 1b clinical trial for Chronic Kidney Disease (CKD).

Who's involved

What this event is mainly about
Gemini

Keep exploring

Part of

Revelation Biosciences, Inc. is advancing its Gemini program and plans to engage with the FDA later this year. All 1 developments

The entities involved

  • Gemini

    US-based cryptocurrency exchange and custodian

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • Zacks Small Cap ResearchREVB To Release Test Results This Quarter By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the developme